Neuroendocrine Tumor – Epidemiology – Epidemiology Dashboard

Clarivate Epidemiology’s coverage of neuroendocrine tumor (NET) comprises epidemiological estimates of key patient populations in 45 countries worldwide. We report both the diagnosed incidence and diagnosed prevalence of NET for each country, as well as annualized case counts projected to the national population.

Most patient populations are forecast over a period of 20 years for the mature markets and Europe, and 10 years for the other countries we cover.

All forecast data are available on Clarivate Insights Platform in tabular format, with options to download to MS Excel. All populations are accompanied by a comprehensive description of the methods and data sources used, with hyperlinks to external sources. A summary evidence table generated as part of our systematic review of the epidemiological literature is also provided for full transparency into research and methods. In addition, we provide a graph depicting the patient flow between or within different disease states for the major mature pharmaceutical markets. These patient-flow diagrams are provided at the regional level but may be requested for any specific country or forecast year.

Clarivate Epidemiology’s NET forecast answers the following questions:

  • In developing countries, what impact will economic growth and development have on the number of people diagnosed with NET each year?
  • Of all people diagnosed with NET, how many in each of the major mature pharmaceutical markets are drug-treated?
  • How will demographic trends, such as population aging and improving life expectancy, affect the epidemiology of NET over the forecast period?

In addition to the total number of cases for each forecast year, Clarivate Epidemiology provides at least 10 years of forecast data for the following NET populations:

  • Diagnosed NET incident cases by stage at diagnosis.
  • Diagnosed NET incident populations by primary site.
  • Diagnosed NET prevalent populations by primary site.
  • Diagnosed metastatic recurrent incident cases
  • Drug-treatable populations

Note: Coverage may vary by country.

launch Related Market Assessment Reports